دورية أكاديمية
أعرض في EDS

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series

التفاصيل البيبلوغرافية
العنوان: Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
المؤلفون: Femin Prasad, Riddhita De, Vittal Korann, Araba F. Chintoh, Gary Remington, Bjørn H. Ebdrup, Dan Siskind, Filip Krag Knop, Tina Vilsbøll, Anders Fink-Jensen, Margaret K. Hahn, Sri Mahavir Agarwal
المصدر: Therapeutic Advances in Psychopharmacology, Vol 13 (2023)
بيانات النشر: SAGE Publishing, 2023.
سنة النشر: 2023
المجموعة: LCC:Therapeutics. Pharmacology
LCC:Psychiatry
مصطلحات موضوعية: Therapeutics. Pharmacology, RM1-950, Psychiatry, RC435-571
الوصف: Metformin is the currently accepted first-line treatment for antipsychotic-associated weight gain (AAWG). However, not all patients benefit from metformin. Glucagon-like peptide-1 receptor agonists (GLP1-RA) have shown promise in the management of obesity in the general population, with preliminary evidence supporting efficacy in AAWG. Semaglutide is a weekly injectable GLP-1RA which received recent approval for obesity management and noted superiority over other GLP-1RAs. This study explored the efficacy and tolerability of semaglutide in AAWG among individuals with severe mental illness. A retrospective chart review of patients treated with semaglutide in the Metabolic Clinic at the Center for Addiction and Mental Health (CAMH) between 2019 and 2021 was conducted. Patients failing a trial of metformin (
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2045-1261
20451253
Relation: https://doaj.org/toc/2045-1261
DOI: 10.1177/20451253231165169
URL الوصول: https://doaj.org/article/b4b4361472ba49fd9f375efebb40983d
رقم الأكسشن: edsdoj.b4b4361472ba49fd9f375efebb40983d
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20451261
20451253
DOI:10.1177/20451253231165169